Pharmacovigilance in India: Present Scenario and Future Challenges
Pharmacovigilance in India was initiated way back in 1986 with a formal adverse drug reaction (ADR) monitoring system, under supervision of the drug controller of India. India joined the World Health Organization (WHO) Programme for International Drug Monitoring in 1998, but was not successful. Later, the National Programme of Pharmacovigilance was launched in 2005, and was renamed as the Pharmacovigilance Programme of India (PvPI) in 2010. In consideration of having a robust pharmacovigilance system in India, steps were taken. The National Coordination Centre was shifted from New Delhi to the Indian Pharmacopoeia Commission (IPC) in Ghaziabad. The PvPI works to safeguard the health of the Indian population by ensuring that the benefit of medicines outweighs the risks associated with their use. The culture of reporting of ADRs has achieved remarkable success, with 250 PvPI-established adverse drug monitoring centres all over India and provision of training to healthcare professionals. The programme is striving hard to build trust between the physician and the patient, thereby increasing patient safety and the confidence of people in the country’s health system, in addition to the detection of substandard medicines and prescribing, dispensing and administration errors. The IPC-PvPI has now become a WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services. In spite of these achievements, several challenges are faced by the PvPI, like the monitoring of generic drugs, biosimilars, and disease-specific ADRs of antidiabetic, cardiovascular and antipsychotic drugs and, above all, creating awareness, which is a continual process. At the same time, the PvPI is trying to address other challenges like counterfeit drugs, antimicrobial resistance, and surveillance during mass vaccinations and other national programmes.
The authors express their sincere gratitude to the Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Ghaziabad, for extending technical support.
Compliance with Ethical Standards
No sources of funding were used to assist in the preparation of this study.
Conflict of interest
V. Kalaiselvan, Sushma Srivastava, Abhishank Singh and S. K. Gupta declare that they have no conflicts of interest.
- 3.World Health Organization A short history of involvement in drug safety monitoring by WHO. In: The importance of pharmacovigilance. Safety monitoring of medicinal products, World Health Organization, Geneva, Switzerland: 2002, p. 5Google Scholar
- 4.World Health Organization. Handbook of resolutions and decisions of the World Health Assembly and Executive Board, Vol 11948–1972. Geneva: World Health Organization; 1973 (WHA16.36 Clinical and pharmacological Evaluation of Drugs).Google Scholar
- 5.World Health Organization. International drug monitoring: the role of national centres (WHO technical report series No. 498). Geneva: World Health Organization; 1972.Google Scholar
- 6.Gupta YK. Pharmacovigilance programme for India. Available at http://www.pharmabiz.com/PrintArticle.aspx?aid=57406&sid=9. Accessed June 2017.
- 9.Gupta YK. Ensuring patient safety—launching the new pharmacovigilance programme of India. Pharma Times. 2010;42(8):21–6.Google Scholar
- 11.Rakesh KR, Rakesh KP, Anil B. Under reporting of ADRs by medical practitioners in India—results of pilot study. Adv Pharmacoepidem Drug Saf. 2012;1:3.Google Scholar
- 12.Pharmacovigilance Programme of India. Introduction & functions. 2017. http://www.ipc.gov.in/PvPI/about.html. Accessed Dec 2017.
- 13.Pharmacovigilance Programme of India. IPC, NCC-PvPI as WHO Collaborating Centre. 2017. http://www.ipc.gov.in/PvPI/about.html. Accessed Nov 2017.
- 14.PvPI. Marketing authorization holders are pivotal in PvPI. PvPI Newsletter. 2017;6(15):8.Google Scholar
- 15.What is a signal? The classic WHO definition. 2017. https://www.who-umc.org/research-scientific-development/signal-detection/what-is-a-signal/. Accessed Nov 2017.
- 16.Haemovigilance Programme of India. National Institute of Biologicals & Indian Pharmacopoeia Commission Collaboration. 2017. http://nib.gov.in/haemovigilance.html. Accessed Nov 2017.
- 17.Pharmacovigilance Programme of India. Organizations involved. 2017. http://www.ipc.gov.in/PvPI/oi.html. Accessed Nov 2017.
- 20.PvPI. Reporting of adverse events due to medical devices is now PvPI’s duty. PvPI Newslett. 2017;7(18):8–9.Google Scholar
- 21.PvPI. Important events. PvPI Newslett. 2016;6(15):4.Google Scholar
- 22.Singh GN. Director’s message. PvPI Newslett. 2017;7(18):3.Google Scholar
- 23.WHO. NRA meets WHO standards on vaccine regulation. PvPI Newslett. 2017;7(18):6.Google Scholar
- 24.Panagariya A. Generic medicines in India: the myth and the truth behind the healthcare issue India. Available at http://www.firstpost.com/india/generic-medicines-in-india-the-myth-and-the-truth-behind-the-healthcare-issue-3413204.html. Accessed March 2018.
- 25.Kaunain Sheriff M. Cheap generic vs costly branded: issues in picking right drug in India. Available at http://indianexpress.com/article/explained/cheap-generic-vs-costly-branded-issues-in-picking-right-drug-in-india-4620165/. Accessed March 2018.
- 26.Nandagopal A, Shakeel Y, Tirunagari M. Biosimilars: current scenario and challenges in India. Acta Pharm. Sci. 2018;56(1):7.Google Scholar
- 33.Singhal R, Khaleel A, Santani DD. Reporting and monitoring of adverse drug reactions with cardiac drugs. Int Res J Pharm. 2011;2(7):116–9.Google Scholar
- 34.Palaniappan M, Selvarajan S, George M, Subramaniyan G, Dkhar SA, Pillai AA, et al. Pattern of adverse drug reactions reported with cardiovascular drugs in a tertiary care teaching hospital. J Clin Diagn Res. 2015. https://doi.org/10.7860/JCDR/2015/13810.6704.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Tarun W, Patil PA, Suresh VP. Monitoring adverse drug reactions in coronary thrombosis patients admitted to intensive cardiac care unit in a tertiary care hospital. Indian J Pharm Pract. 2013;6(1):6–12.Google Scholar
- 36.International Diabetes Federation. Belgium. Available from: http://www.diabetesatlas.org/across-the-globe.html. [Accessed on January 11, 2016].
- 38.Indian Diabetes Market Report & Outlook for 2010-2015. Press release. Available from: http://www.mynewsdesk.com/in/pressreleases/indian-diabetes-market-report-outlook-for-2010-2015-through-bharatbook-com-586410. Accessed on November 26, 2015.
- 43.Kurmi P, Paul PK, Dutta SK, Das S. To study the pattern of adverse drug reaction of antipsychotic drugs in a tertiary care hospital of Assam. Int J PharmTech Res. 2015;8:101–5.Google Scholar
- 45.Tiwari SC, Srivastava G, Tripathi RK, Pandey NM, Agarwal GG, Pandey S, Tiwari S. Prevalence of psychiatric morbidity amongst the community dwelling rural older adults in northern India. IJMR. 2013;138(4):505–14.Google Scholar
- 47.Bhupendra Raj, Prabhakar Singh, Pankaj More, Manoj Indurkar, Vivek Pandey. Prospective study of adverse drug reactions monitoring in a tertiary care hospital, Rewa (MP). Sch J App Med Sci. 2016;4(11C):4023–7.Google Scholar
- 49.Hema NG, Bhuvana KB, Sangeetha. Pharmacovigilance: the extent of the awareness among the final year students, interns and postgraduates (PGs) in a government teaching hospital. J Clin Diagn Res. 2012;6(7):1248–53.Google Scholar